

**Overview**
**Useful For**

Monitoring for appropriate therapeutic concentration of both free and total phenytoin: free phenytoin level is the best indicator of adequate therapy in renal failure

**Profile Information**

Test ID	Reporting Name	Available Separately	Always Performed
PNYF	Phenytoin, Free, S	Yes	Yes
PNYA	Phenytoin, Total, S	Yes	Yes

**Method Name**

PNYF: Membrane Separation/KIMS

PNYA: Kinetic interaction of Microparticles in a Solution (KIMS)

**NY State Available**

Yes

**Specimen**
**Specimen Type**

Serum Red

**Specimen Required**

**Container/Tube:** Red top

**Specimen Volume:** 2 mL

**Collection Instructions:** Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.

**Forms**

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

**Specimen Minimum Volume**

1 mL

**Reject Due To**

Gross hemolysis	Reject
-----------------	--------

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum Red	Refrigerated (preferred)	7 days	
	Frozen	14 days	
	Ambient	7 days	

## Clinical and Interpretive

### Clinical Information

Phenytoin is the drug of choice to treat and prevent tonic-clonic and psychomotor seizures. If phenytoin alone will not prevent seizure activity, coadministration with phenobarbital is usually effective.

Initial therapy with phenytoin is started at doses of 100 to 300 mg/day for adults or 4 mg/kg/day for children. Because absorption is variable and the drug exhibits zero-order (nonlinear) kinetics, dose must be adjusted within 5 days using blood concentration to guide therapy. Oral bioavailability ranges from 80% to 95% and is diet-dependent.

Phenytoin exhibits zero-order pharmacokinetics; the rate of clearance of the drug is dependent upon the concentration of drug present. Therefore, phenytoin does not have a classical half-life like other drugs, since it varies with blood concentration. At a blood concentration of 15 mcg/mL, approximately half the drug in the patient's body will be eliminated in 20 hours. As the blood concentration drops, the rate at which phenytoin is excreted increases.

Phenytoin has a volume of distribution of 0.65 L/kg, and is highly protein bound (90%), mostly to albumin.

Phenytoin pharmacokinetics are significantly affected by a number of other drugs. Phenytoin and phenobarbital are frequently coadministered. Induction of the cytochrome P450 enzyme system by phenobarbital will increase the rate at which phenytoin is metabolized and cleared. At steady-state, enzyme induction will increase the rate of clearance of phenytoin such that the dose must be increased approximately 30% to maintain therapeutic levels.

Uremia has a similar effect on phenytoin protein binding. In uremia, by-products of normal metabolism accumulate and bind to albumin, displacing phenytoin, which causes an increase in the free (active) fraction.

Concurrent use of phenytoin and valproic acid (another frequently used antiepileptic) may result in altered valproic acid levels and/or altered phenytoin levels. Due to the complex situation involving displacement of protein-bound phenytoin and inhibition of phenytoin metabolism, as well as the potential for decreased valproic acid concentrations, patients should be monitored for both phenytoin toxicity and therapeutic efficacy. Free phenytoin levels should be measured to provide the most accurate assessment of phenytoin activity early in therapy. At steady-state, free phenytoin and free valproic acid concentrations should be normalized.

The free phenytoin level is the best indicator of adequate therapy.

In renal failure, the opportunity for the free phenytoin fraction to be cleared is significantly reduced. The end result is that both the total and free concentration of phenytoin increase, with the free concentration increasing faster than the total. Dosage must be reduced to avoid toxicity. Accordingly, the free phenytoin level is the best indicator of adequate therapy in renal failure.

Toxicity is a constant possibility because of the manner in which phenytoin is metabolized. Small increases in dose can lead to very large increases in blood concentration, resulting in early signs of toxicity such as nystagmus, ataxia, and dysarthria. Severe toxicity is typified by tremor, hyperreflexia, lethargy, and coma. The outcome of phenytoin toxicity is not as serious as phenobarbital because phenytoin is not a central nervous system sedative.

**Reference Values**

Phenytoin, Total

Therapeutic: 10.0-20.0 mcg/mL

Critical value: &gt; or =30.0 mcg/mL

Phenytoin, Free

Therapeutic: 1.0-2.0 mcg/mL

Critical value: &gt; or =2.5 mcg/mL

**Interpretation**

Dose should be adjusted to achieve steady-state concentrations of total phenytoin between 10.0 and 20.0 mcg/mL, and free phenytoin between 1.0 and 2.0 mcg/mL. The range for percent free phenytoin is 8% to 14%. However, response and side effects will be individual.

In patients with renal failure, total phenytoin is likely to be less than the therapeutic range of 10.0 to 20.0 mcg/mL. Severe toxicity occurs when the total blood concentration exceeds 30.0 mcg/mL.

**Cautions**

Toxicity is a constant possibility because of the manner in which phenytoin is metabolized. Small increases in dose can lead to very large increases in blood concentration, resulting in early signs of toxicity such as nystagmus, ataxia, and dysarthria. Severe toxicity occurs when the blood concentration is >30 mcg/mL and is typified by tremor, hyperreflexia, lethargy, and coma.

**Clinical Reference**

1. Richens A: Clinical pharmacokinetics of phenytoin. *Clin Pharmacokinet* 1979;4:153-169
2. Moyer TP: Therapeutic drug monitoring. In *Tietz Textbook of Clinical Chemistry*. Fourth edition. Edited by CA Burtis, ER Ashwood. Philadelphia, WB Saunders Company, 2005, pp 1237-1285

**Performance****Method Description**

Free phenytoin is isolated from serum by ultrafiltration. The phenytoin assay is based on the kinetic interaction of microparticles in a solution (KIMS). Phenytoin antibody is covalently coupled to microparticles and the drug derivative is linked to a macromolecule. The kinetic interaction of microparticles in solutions is induced by binding of drug-conjugate to the antibody on the microparticles and is inhibited by the presence of phenytoin in the sample. A competitive reaction takes place between the drug conjugate and phenytoin in the serum sample for binding to the phenytoin antibody on the microparticles. The resulting kinetic interaction of microparticles is indirectly proportional to the amount of drug present in the sample. Fresh serum subjected to ultra-filtration to generate a protein-free filtrate, which is then analyzed for free phenytoin by KIMS. (Package insert: Roche Phenytoin reagent, Roche Diagnostic Corp, Indianapolis, IN)

**PDF Report**

No

**Day(s) and Time(s) Test Performed**

---

Monday through Sunday; Continuously

**Analytic Time**

Same day/1 day

**Maximum Laboratory Time**

1 day

**Specimen Retention Time**

1 week

**Performing Laboratory Location**

Rochester

**Fees and Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

**CPT Code Information**

Phenytoin, total-80185

Phenytoin, free-80186

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
PNTFT	Phenytoin, Total and Free, S	34540-5

Result ID	Test Result Name	Result LOINC Value
PNYF	Phenytoin, Free, S	3969-3
PNYA	Phenytoin, Total, S	3968-5